Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Clinical Oncology and Rehabilitation》 2004-04
Add to Favorite Get Latest Update

Gemcitabine plus cisplatin vs navelbine plus cisplatin in treatment of elderly patients with advanced non small cell lung cancer

LI Wei dong,PENG Mei fang,LI Hui hang,et al (The Second Chemotherapy Department,Tumor Hospital of Guangzhou,Guangzhou 510095,China)  
Objective To evaluate and compare the therapeutic efficacy and toxicity between combination of gemcitabine and cisplatin (GP) and combination of navelbine and cisplatin (NP) in elderly patients with advanced non small cell lung cancer(NSCLC).Methods Sixty one patients with local advanced or metastatic NSCLC were enrolled into the study,with 30 patients in GP group and 31patients in NP group. Patients' characteristics were similar between the two groups.They were given gemcitabine 1000 mg/m 2 or navelbine 25 mg/m 2 on days 1 and 8,and cisplatin 80 100 mg/m 2 on day 1.The chemotherapy was repeated every 3 weeks as a cycle.Results Objective response rate of 40.0% was observed in GP group versus 38.7% in NP group( P =0.58).The 1 year survival rate was 34.8% in GP group and 30.0% in NP group( P =0.51). The median survival duration was 9.3 months in GP group and 8.8 months in NP group. Myelosuppression was the major dose-limiting toxicity. The incidence of gradeⅢ/Ⅳ leukopenia was significantly higher in the NP group than in the GP group( P = 0.01 ),while gradeⅢ/Ⅳ thrombocytopenia occurred more frequently in the GP group than in NP group( P = 0.016 ).Conclusion The GP combination is as equally active and well tolerated as the NP combination in elderly patients with advanced non-small cell lung cancer.
【CateGory Index】: R734.2
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved